<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01785511</url>
  </required_header>
  <id_info>
    <org_study_id>UVA Study</org_study_id>
    <nct_id>NCT01785511</nct_id>
  </id_info>
  <brief_title>Does Ultraviolet Irradiation Reduce Platelet Reactivity and Improve Coronary Microvascular Function in Man?</brief_title>
  <official_title>Does Ultraviolet Irradiation Reduce Platelet Reactivity and Improve Coronary Microvascular Function in Man?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endothelium derived nitric oxide (NO) regulates vascular tone and blood pressure in man. NO&#xD;
      also inhibits platelet aggregation and mediates a variety of beneficial anti-inflammatory and&#xD;
      repair mechanisms. NO may also be a mediator in the release of the endogenous fibrinolytic&#xD;
      factor, tissue-plasminogen activating factor (t-PA) from the endothelium.1 Via these actions&#xD;
      it plays a very important role in protection of the vasculature from atherothrombosis and&#xD;
      clinical sequelae such as myocardial infarction and stroke.&#xD;
&#xD;
      Visible and ultraviolet (UV) light relax vascular smooth muscles by producing NO in a&#xD;
      phenomenon known as photorelaxation.2 The investigators have demonstrated significant stores&#xD;
      of pre-formed, bound NO and other nitrosospecies in human skin, which are rapidly released&#xD;
      upon exposure to UVA.3 The investigators have demonstrated recently that serum nitrite and&#xD;
      nitroso-species are increased after standing in a UVA phototherapy cabinet and that local UVA&#xD;
      exposure is associated with increased forearm arterial blood flow that is independent of skin&#xD;
      temperature. The investigators have also demonstrated a fall in mean arterial blood pressure&#xD;
      in subjects exposed UVA.&#xD;
&#xD;
      Cardiovascular morbidity and the prevalence of hypertension vary with latitude. The&#xD;
      investigators hypothesise that some of this geographical variation may be explained by a&#xD;
      diminished sunlight/UVA exposure with attendant negative effects upon NO bio-availability.4&#xD;
      To further examine the potential beneficial effects of UVA exposure we will examine the&#xD;
      effects of whole-body UVA upon platelet activation and upon myocardial/coronary arterial flow&#xD;
      reserve. The investigators will correlate these measures with systemic nitrate, nitrite and&#xD;
      nitroso-species content in healthy volunteers.&#xD;
&#xD;
      HYPOTHESES&#xD;
&#xD;
        1. UVA irradiation enhances coronary flow reserve in healthy volunteers.&#xD;
&#xD;
        2. UVA irradiation suppresses platelet activation in healthy volunteers.&#xD;
&#xD;
        3. UVA irradiation enhances the release of endogenous fibrinolytic factors in healthy&#xD;
           volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary Flow Reserve</measure>
    <time_frame>0, 20, 40 and 60 mins</time_frame>
    <description>Change in coronary flow assessed pre and post UVA radiation versus control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet Activation</measure>
    <time_frame>0, 20, 40 and 60 mins</time_frame>
    <description>Platelet activation assessed using platelet monocyte activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endogenous Fibrinolysis</measure>
    <time_frame>0, 20, 40 and 60 minutes</time_frame>
    <description>Assessed using flow cytometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Sham UVA</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>sham exposure will be provided by covering the UVA lamps with space blanket.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UVA Radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be exposed to UVA radiation for 20 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>UVA Radiation</intervention_name>
    <description>UVA radiation exposure for 20 minutes</description>
    <arm_group_label>Sham UVA</arm_group_label>
    <arm_group_label>UVA Radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male volunteers aged between 18-45 years (inclusive).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Co-existent systemic disease (including any history of asthma, reactive airways&#xD;
             disease or hypertension)&#xD;
&#xD;
          -  Contraindication to UVA treatment&#xD;
&#xD;
          -  Any history of cardiac conduction abnormality (including bundle branch block or atrial&#xD;
             fibrillation)&#xD;
&#xD;
          -  Smoker&#xD;
&#xD;
          -  Current intake of aspirin, other non-steroid anti-inflammatory medications or any&#xD;
             regular medication.&#xD;
&#xD;
          -  Recent infective/inflammatory condition&#xD;
&#xD;
          -  Echocardiographic evidence of left ventricular hypertrophy (left ventricular septal&#xD;
             diameter &gt;1.2 cm in diastole), systolic dysfunction or significant valvular stenosis&#xD;
             or regurgitation.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ninian Lang, MbChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Lothian</state>
        <zip>Eh16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>June 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2013</study_first_posted>
  <last_update_submitted>February 19, 2013</last_update_submitted>
  <last_update_submitted_qc>February 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>UV radiation</keyword>
  <keyword>coronary flow reserve</keyword>
  <keyword>nitric oxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

